DALLAS, April 22, 2026 - Scientific research teams from Mass General Brigham Heart and Vascular Institute in Boston, Cincinnati Children's Hospital Center and the University of Pittsburgh will lead a new $15 million initiative dedicated to better understanding how to diagnose and treat heart valve disease . The Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease is the latest research network funded by the American Heart Association, a global force changing the future of health for all.
According to the American Heart Association's 2026 Heart Disease and Stroke Statistics , more than 80 million people worldwide are living with some type of heart valve disease, and the numbers are climbing. In the U.S., the condition contributes to more than 57,000 deaths each year.
Heart valve disease is a common cardiovascular condition in which one or more of the heart's four valves are narrowed and restrict blood flow or do not close properly which causes blood to flow backward rather than into the heart chambers or large blood vessels.
The American Heart Association (AHA) has awarded a four‑year, $15 million grant to a multi‑center research network intended to improve early detection and slow progression of valvular heart disease.
The program, titled the Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease, began April 1, 2026, and will support collaborative research activities led by teams from Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Medical Center, and the University of Pittsburgh.
The AHA frames this funding as a continuation of its strategic investment in disease‑focused research networks aimed at addressing priority knowledge gaps in cardiovascular health.
The AHA’s 2026 Heart Disease and Stroke Statistics, cited in the source, estimate that more than 80 million people worldwide are living with some form of heart valve disease and indicate that prevalence is increasing.
In the United States, the condition is noted to contribute to over 57,000 deaths annually.
The source describes valvular heart disease as dysfunction of one or more of the heart’s four valves, manifesting either as stenosis (narrowing with restricted forward flow) or regurgitation (inadequate closure with backward flow).
The AHA emphasizes that the disorder can progress silently with advancing age, that many patients are unaware until symptoms appear, and that untreated disease may lead to heart failure, arrhythmias, recurrent hospital admissions, impaired quality of life, and premature death.
The stated problem motivating the network is the need to identify early warning signs and diagnosis before symptom onset so that a broader range of management options and complication prevention strategies may be available.
The award supports three funded centers that will conduct collaborative projects.
The source names lead investigators associated with the funded centers: Andrea Beaton, M.D., M.S., FAHA (professor of pediatrics at the University of Cincinnati and pediatric cardiologist, Cincinnati Children’s Hospital Medical Center); Elena Aikawa, M.D., Ph.D., FAHA (director of the Heart Valve Translational Research Program at Brigham and Women’s Hospital, affiliated with Mass General Brigham); and Cynthia St.
Hilaire, Ph.D., FAHA (director of the Center for Integrative Valve Science and associate professor of medicine at the University of Pittsburgh).
The narrative states that the program will include collaborative research projects across these centers but does not provide specifics of individual project designs, sample sizes, exact aims, or detailed methods within the source text.
The source situates this network within a long‑standing AHA program of Strategically Focused Research Networks.
The AHA reports having invested nearly $300 million to establish 19 such networks, each targeting a strategically prioritized research topic identified by the Association’s volunteer Board of Directors.
Prior networks have addressed diverse topics—prevention, hypertension, women’s cardiovascular health, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias and sudden cardiac death, cardiometabolic disease and type 2 diabetes, health technology, cardio‑oncology, chronic psychosocial stress, inflammation in cardiovascular health, and cardiovascular‑kidney‑metabolic syndrome.
Networks are described as multidisciplinary assemblies typically composed of three to six centers, bringing together expertise across basic, clinical, and population/behavioral science to advance diagnosis, prevention, and treatment.
The AHA reports that it has funded more than $6.1 billion in cardiovascular, cerebrovascular, and brain health research since 1949 and identifies itself as the single largest nonprofit, nongovernmental funder of heart and brain health research in the United States.
The Association frames the current awards as part of its century‑long mission to generate knowledge that saves lives and impacts populations domestically and globally.
The source also notes public trust metrics from an Annenberg Policy Center poll, stating that 82% of U.S.
adults express confidence in the AHA as a source of trustworthy public health information, ranking it second only to an individual’s personal health care provider.
The explicit aim described in the source is to improve understanding about how to detect valvular heart disease earlier and how to delay its progression.
The AHA characterizes the research network as a mechanism to extend the organization’s prior quality improvement and clinical programs—such as its Heart Valve Initiative and the Target: Aortic Stenosis quality improvement program—by supporting hypothesis‑driven, “cutting‑edge” scientific exploration at earlier stages of disease.
The source indicates the expectation that the funded teams will generate new knowledge relevant to diagnosis, prevention, and treatment pathways, but does not enumerate specific biomarkers, diagnostic tools, or therapeutic approaches to be investigated.
The awards span four years and commenced on April 1, 2026.
The source indicates that the centers will conduct collaborative research projects across institutions.
No operational details were provided regarding governance structure, data sharing arrangements, core facilities, biorepositories, or timelines for interim deliverables and dissemination plans.
The source does not report specific study designs, hypotheses, protocols, eligibility criteria, sample sizes, endpoints, statistical plans, or planned analytic approaches for the collaborative projects.
It does not provide details on funding allocation among centers, mechanisms for external oversight or peer review of project milestones, or how early detection and progression‑delaying strategies will be operationalized in clinical settings.
Patient populations to be studied (for example, age ranges, community versus clinical cohorts), planned biomarker or imaging modalities, and expected outcome measures were not described.
As a news release from the funding organization, the piece provides high‑level context and named investigators but lacks granular methodological information.
The AHA frames the network as responsive to an increasing burden of valvular heart disease and the need for earlier diagnosis to expand treatment options and prevent complications.
The source positions the initiative as complementary to existing AHA clinical quality programs and as a vehicle to generate scientific advances that could inform future care pathways.
Specific clinical or policy implications beyond these general aspirations were not detailed in the release.